This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Erridge, C. Articles by Poxton, I. R. Search for Related Content PubMed PubMed Citation Articles by Erridge, C. Articles by Poxton, I. R. Social Bookmarking                         What's this?

The biological activity of a liposomal complete core lipopolysaccharide vaccine

Medical Microbiology, University of Edinburgh Medical School, Edinburgh, UK

John Stewart

Medical Microbiology, University of Edinburgh Medical School, Edinburgh, UK

Elliott Bennett-Guerrero

Department of Anesthesiology, Columbia University College of Physicians & Surgeons, New York, USA

Thomas J. McIntosh

Department of Cell Biology, Duke University, Durham, North Carolina, USA

Ian R. Poxton

Medical Microbiology, University of Edinburgh Medical School, Edinburgh, UK, i.r.poxton{at}ed.ac.uk

A vaccine that induces humoral immunity to lipopolysaccharide (LPS), while remaining non-pyrogenic should be beneficial, as high levels of antibodies against LPS are associated with a reduced risk of adverse outcome. However, pure LPS or bacteria expressing LPS are generally considered too toxic to be used as vaccines. Recently, a novel, immunogenic complete core lipopolysaccharide vaccine has been described, which has been designed to prevent endotoxin-related inflammatory reactions in surgical and high-risk hospitalized patients. In vivo studies have shown that while administration of the vaccine to rabbits results in no toxicity over 7 days, it does induce significantly enhanced antibody responses towards a broad range of clinically relevant Gram-negative LPSs. Here we show that encapsulation of the four complete core LPS types Escherichia coli K12, Escherichia coli R1, Bacteroides fragilis and Pseudomonas aeruginosa into liposomes greatly reduces the ability of a given amount of LPS to induce TNF- production in vitro from human monocytes. In contrast to previous studies of liposomal LPS, we demonstrate a reduction in activity of approximately 100,000-fold; a reduction approximately 100—1,000-fold more than that previously described. The signalling by the liposomal LPS appears to be entirely dependent on serum factors, though this can be partially restored by soluble CD14 or, to a lesser extent, by lipopolysaccharide binding protein. Time-course experiments reveal that liposomal LPS signalling shows similar kinetics to pure LPS signalling. Therefore, as well as inducing specific antibody responses, liposomal LPS demonstrates characteristics suitable for use as a vaccine to be used in human beings.

Journal of Endotoxin Research, Vol. 8, No. 1, 39-46 (2002)
DOI: 10.1177/09680519020080010401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?